Belvedere Trading
IMVT icon

Belvedere Trading’s Immunovant IMVT Stock Holding History

Belvedere Trading’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,461
Closed -$385K – 896
2023
Q3 		$402K Buy
+10,461
New +$236K ﹤0.01% 139
2021
Q4 		– Sell
-6,621
Closed -$57K – 529
2021
Q3 		$57K Buy
+6,621
New +$59.7K ﹤0.01% 408

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Belvedere Trading's IMVT Position: Q4 2023 in Review

Belvedere Trading sold out of Immunovant (IMVT) in Q4 2023, closing a stake of 10,461 shares — an estimated $385K sold.

Belvedere Trading first reported a position in IMVT in Q3 2021 and held it in 2 quarters. The position peaked at $402K in Q3 2023. 228 funds tracked by Wall St. Rank hold IMVT as of Q4 2023.

  • Belvedere Trading reported no remaining Immunovant position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 10,461 Immunovant shares in Q4 2023, an estimated $385K.
  • Belvedere Trading first reported a position in Immunovant in Q3 2021 and held it in 2 quarters.
  • Belvedere Trading's Immunovant position peaked at $402K in Q3 2023.
  • 228 funds tracked by Wall St. Rank held Immunovant as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.